Список литературы к Главе 18

26. Döhner H. et al. Genomic aberrations and survival in chronic lymphocytic leukemia // N. Engl. J. Med. 2000. Vol. 343, N 26. P. 1910–1916. DOI: https://doi.org/10.1056/NEJM200012283432602

27. Catherwood M.A. et al. Relevance of TP53 for CLL diagnostics // J. Clin. Pathol. 2019. Vol. 72, N 5. P. 343–346. DOI: https://doi.org/10.1136/jclinpath­2018­205622 Epub 2019 Feb 2. PMID: 30712002.

28. Baliakas P. et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact // Blood. 2019. Vol. 133, N 11. P. 1205–1216. DOI: https://doi.org/10.1182/blood­2018­09­873083

29. Kröber A. et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia // Blood. 2002. Vol. 100, N 4. P. 1410–1416.

30. Zenz T. et al. From pathogenesis to treatment of chronic lymphocytic leukaemia // Nat. Rev. Cancer. 2010. Vol. 10, N 1. P. 37–50. DOI: https://doi.org/10.1038/nrc2764

31. Ten Hacken E. et al. The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia // Leukemia. 2019. Vol. 33, N 2. P. 287–298. DOI: https://doi.org/10.1038/s41375­018­0303­x

32. Hamblin T.J. et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia // Blood. 1999. Vol. 94, N 6. P. 1848–1854.

33. Damle R.N. et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia // Blood. 1999. Vol. 94, N 6. P. 1840–1847.

34. Thompson P.A. et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long­term disease­free survival in IGHV­mutated chronic lymphocytic leukemia // Blood. 2016. Vol. 127, N 3. P. 303–309. DOI: https://doi.org/10.1182/blood­2015­09­667675

35. Agathangelidis A. et al. Higher­order connections between stereotyped subsets: implications for improved patient classification in CLL // Blood. 2021. Vol. 137, N 10. P. 1365–1376. DOI: https://doi.org/10.1182/blood.2020007039 PMID: 32992344.

36. Baliakas P. et al. European Research Initiative on CLL (ERIC). Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia // Haematologica. 2019. Vol. 104, N 2. P. 360–369. DOI: https://doi.org/10.3324/haematol.2018.195032 Epub 2018 Sep 27. PMID: 30262567; PMCID: PMC6355487.

37. Dartigeas C. et al.; CLL 2007 SA Investigators; French Innovative Leukemia Organization (FILO). Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open­label, randomised phase 3 study // Lancet Haematol. 2018. Vol. 5, N 2. P. e82–e94. DOI: https://doi.org/10.1016/S2352­3026(17)30235­1 Epub 2017 Dec 20. PMID: 29275118.

38. Tertian G. et al. Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia // Hematol. Cell Ther. 1996. Vol. 38, N 4. P. 359–360. DOI: https://doi.org/10.1007/s00282­996­0359­3

39. Longo G. et al. Fludarabine and autoimmune hemolytic anemia in chronic lymphocytic leukemia // Eur. J. Haematol. 1997. Vol. 59, N 2. P. 124–125. DOI: https://doi.org/10.1111/j.1600­0609.1997.tb00737.x

40. Taha H.M., Narasihman P., Venkatesh L., Cawley M., Kaplan B. Fludarabine­related hemolytic anemia in chronic lymphocytic leukemia and lymphoproliferative disorders // Am. J. Hematol. 1998. Vol. 59, N 4. P. 316. DOI: https://doi.org/10.1002/(sici)1096­8652(199812)59:4<316::aid­ajh8>3.0.co;2­g

41. Gonzalez H. et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine // Hematol. Cell Ther. 1998. Vol. 40, N 3. P. 113–118.

42. Martell R.E. et al. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CAL­GB (9011) coordinated intergroup study // Cancer Chemother. Pharmacol. 2002. Vol. 50, N 1. P. 37–45. DOI: https://doi.org/10.1007/s00280­002­0443­5

43. Hersh M.R. et al. Pharmacokinetic study of fludarabine phosphate (NSC 312887) // Cancer Chemother. Pharmacol. 1986. Vol. 17. P. 277–280.

44. Lichtman S.M. et al. Development of a fludarabine phosphate (FAMP) dosing formula in patients with renal insufficiency based on a pharmacokinetic (PK) study in patients with and without renal impairment // Proc. Am. Soc. Clin. Oncol. 1998. Vol. 17. Abstr. 845.

45. Leporrier M. et al. Pure red­cell aplasia with fludarabine for chronic lymphocytic leukaemia // Lancet. 1993. Vol. 342, N 8870. P. 555.

46. Elefante A., Czuczman M.S. Bendamustine for the treatment of indolent non­Hodgkin’s lymphoma and chronic lymphocytic leukemia // Am. J. Health Syst. Pharm. 2010. Vol. 67, N 9. P. 713–723. DOI: https://doi.org/10.2146/ ajhp090328

47. Cuneo A. et al. Appropriate use of bendamustine in first­line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group // Leuk. Res. 2014. Vol. 38, N 11. P. 1269–1277. DOI: https://doi.org/10.1016/j.leukres.2014.06.017

48. Eichhorst B. et al. First­line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open­label, randomised, phase 3, non­inferiority trial // Lancet Oncol. 2016. Vol. 17, N 7. P. 928–942. DOI: https://doi.org/10.1016/S1470­2045(16)30051­1

49. Ahn I.E. et al. Early progression of disease as a predictor of survival in chronic lymphocytic leukemia // Blood Adv. 2017. Vol. 1, N 25. P. 2433–2443. DOI: https://doi.org/10.1182/bloodadvances.2017011262 Epub 2017 Nov 28.

50. Tam C.S. et al. Long­term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia // Blood. 2008. Vol. 112, N 4. P. 975–980. DOI: https://doi.org/10.1182/blood­2008­02­140582 Epub 2008 Apr 14. PMID: 18411418; PMCID: PMC3952498.

51. Hallek M. et al.; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open­label, phase 3 trial // Lancet. 2010. Vol. 376, N 9747. P. 1164–1174. DOI: https://doi.org/10.1016/S0140­6736(10)61381­5 PMID: 20888994.

52. Fischer K. et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group // J. Clin. Oncol. 2012. Vol. 30, N 26. P. 3209–3216. DOI: https://doi.org/10.1200/JCO.2011.39.2688 Epub 2012 Aug 6. PMID: 22869884.

53. Eichhorst B. et al.; International Group of Investigators; German CLL Study Group (GCLLSG). First­line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open­label, randomised, phase 3, non­inferiority trial // Lancet Oncol. 2016. Vol. 17, N 7. P. 928–942. DOI: https://doi.org/10.1016/S1470­2045(16)30051­1 Epub 2016 May 20. PMID: 27216274.

54. Michallet A.S. et al. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open­label MABLE study // Haematologica. 2018. Vol. 103, N 4. P. 698–706. DOI: https://doi.org/10.3324/haematol.2017.170480 Epub 2018 Feb 1. PMID: 29419437; PMCID: PMC5865431.

55. Choi Y.W. et al. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B­cell lymphoma patients treated with rituximab­CHOP // J. Korean Med. Sci. 2014. Vol. 29, N 11. P. 1493–1500. DOI: https://doi.org/10.3346/jkms.2014.29.11.1493 Epub 2014 Nov 4. PMID: 25408580; PMCID: PMC4234916.

56. Limat S. et al. Early cardiotoxicity of the CHOP regimen in aggressive non­Hodgkin’s lymphoma // Ann. Oncol. 2003. Vol. 14, N 2. P. 277–281. DOI: https://doi.org/10.1093/annonc/mdg070 PMID: 12562656.

57. Goede V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions // N. Engl. J. Med. 2014. Vol. 370, N 12. P. 1101–1110. DOI: https://doi.org/10.1056/NEJMoa1313984

58. Landau D.A. et al. Mutations driving CLL and their evolution in progression and relapse // Nature. 2015. Vol. 526, N 7574. P. 525–530. DOI: https://doi.org/10.1038/nature15395 Epub 2015 Oct 14. PMID: 26466571; PMCID: PMC4815041.

59. Dreger P. et al.; Chronic Leukemia Working Party of the EBMT. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus // Leukemia. 2007. Vol. 21, N 1. P. 12–17. DOI: https://doi.org/10.1038/sj.leu.2404441 Epub 2006 Nov 16. PMID: 17109028.

60. Tam C.S. et al. Long­term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab) // Blood. 2014. Vol. 124, N 20. P. 3059–3064. DOI: https://doi.org/10.1182/blood­2014­06­583765 Epub 2014 Oct 3. PMID: 25281606; PMCID: PMC4231417.

61. Byrd J.C. et al. Ibrutinib treatment for first­line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC­1102 study // Clin. Cancer Res. 2020. Vol. 26, N 15. P. 3918–3927. DOI: https://doi.org/10.1158/1078­0432.CCR­19­2856 Epub 2020 Mar 24. PMID: 32209572.

62. Rossi D. et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia // Blood. 2014. Vol. 123, N 14. P. 2139–2147. DOI: https://doi.org/10.1182/blood­2013­11­539726 Epub 2014 Feb 5. PMID: 24501221; PMCID: PMC4017291.

63. Nadeu F. et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia // Blood. 2016. Vol. 127, N 17. P. 2122–2130. DOI: https://doi.org/10.1182/blood­2015­07­659144 Epub 2016 Feb 2. PMID: 26837699; PMCID: PMC4912011.

64. Yu L. et al. Survival of Del17p CLL depends on genomic complexity and somatic mutation // Clin. Cancer Res. 2017. Vol. 23, N 3. P. 735–745. DOI: https://doi.org/10.1158/1078­0432.CCR­16­0594 Epub 2016 Aug 8. PMID: 27503198; PMCID: PMC5467311.